GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that revenue for the first quarter of 2017 increased 6% to $69.5 million from $65.3 million in the first quarter of 2016, and 7% on a constant currency basis. Domestic revenue increased 7% to $47.7 million and international revenue increased 5% to $21.8 million in the first quarter of 2017. Diluted earnings per share for the first quarter was $0.32 based on net income of $4.6 million, compared to first quarter 2016 net income of $4.4 million and diluted earnings per share of $0.31.
First Quarter Segment Performance
- Extremity revenues increased 21% to $30.0 million from $24.8 million, a 21% constant currency increase
- Knee revenue increased 1% to $20.0 million from $19.8 million, a 1% constant currency increase
- Hip revenue increased 6% to $12.1 million from $11.4 million, a 6% constant currency increase
- Other revenues decreased 20% to $7.3 million from $9.2 million, a 19% constant currency decrease. The Other segment includes an aggregation of the former Biologics and Spine segment
Exactech CEO and President David Petty said, “With three new revision systems now in full launch, we leveraged our sales channel and improvements in our supply chain to deliver a strong start to 2017. The innovative features of our Optetrak Logic® CC revision knee and Alteon® Monobloc hip systems continue to attract new surgeons, improve patient outcomes and post growth in those segments. Our extremities business continued to accelerate, attracting record attendance at our global medical education programs. At the ten-year clinical milestone, our Equinoxe® reverse platform shoulder system remains a core driver of customer satisfaction while new products like our humeral reconstruction prosthesis contribute to a robust new customer pipeline.
“The sales increase of 6% to $69.5 million was above our expectations as domestic revenue increased 7% to $47.7 million, and excluding the impact of the divested US spine assets during the quarter, domestic sales increased 11%. International revenue increased 5% to $21.8 million, and a 7% increase on a constant currency basis,” Petty said.
Chief Financial Officer Jody Phillips said, “Gross margins increased to 70% from 69% for the first quarter a year ago due to strength in our US extremities business. Total operating expenses for the quarter increased 10% to $42.5 million primarily due to heavy investments we continue to make in our product development pipeline with research and development expenses increasing 23% during the quarter. Sales and marketing expenses increased 7% to $25.1 million due to variable selling expenses and investments in our medical education and training programs. Transition costs associated with divestiture of our spine assets were less than originally projected at a total of $0.5 million resulting in a $0.02 diluted EPS impact on the quarter and as a result we produced a net income increase of 4% to $4.6 million for the quarter."
Looking forward, Exactech updated 2017 revenue guidance to $266-$272 million and increased diluted EPS target to $1.24-$1.30, including the impact of the first quarter $0.02 diluted earnings per share costs related to the spine business transition. On an adjusted basis, the diluted EPS target is $1.26-$1.32. For the second quarter of 2017, the company anticipates revenues of $66.5-$68.5 million and diluted EPS of $0.32-$0.34. The foregoing statements regarding targets for the quarter and full year are forward-looking and actual results may differ materially. These are the company’s targets, not predictions of actual performance.
The financial statements are below.
The company will hold a conference call with CEO David Petty and key members of the management team Wednesday, April 26th at 10:00 a.m. Eastern Time. The call will cover Exactech’s first quarter 2017 results. Mr. Petty will open the conference call and a question-and-answer session will follow.
To participate in the call, dial 877-874-1569 any time after 9:50 a.m. Eastern Time on April 26. International and local callers should dial 719-325-4888. A live webcast of the call will be available at http://www.hawkassociates.com/profile/exac.cfm or http://public.viavid.com/index.php?id=123876.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
EXACTECH, INC. AND SUBSIDIARIES
|CONSOLIDATED BALANCE SHEETS|
|March 31,||December 31,|
|Cash and cash equivalents||$||11,173||$||13,052|
|Trade receivables, net of allowances of $1,641 and $1,473||58,596||53,051|
|Prepaid expenses and other assets, net||4,119||3,075|
|Income taxes receivable||2,487||2,140|
|Assets held for sale||—||6,477|
|Total current assets||142,564||143,059|
|PROPERTY AND EQUIPMENT:|
|Machinery and equipment||42,447||42,034|
|Furniture and fixtures||4,864||4,700|
|Projects in process||5,457||2,473|
|Total property and equipment||218,795||207,541|
|Net property and equipment||114,322||107,307|
|Deferred financing and deposits, net||800||968|
|Deferred tax asset||—||887|
|Product licenses and designs, net||8,860||9,102|
|Patents and trademarks, net||769||821|
|Customer relationships, net||488||476|
|Total other assets||40,209||43,843|
|LIABILITIES AND SHAREHOLDERS’ EQUITY|
|Income taxes payable||1,425||780|
|Other current liabilities||2,805||2,927|
|Total current liabilities||35,409||33,105|
|Deferred tax liabilities||2,458||1,773|
|Long-term debt, net of current portion||16,000||20,000|
|Other long-term liabilities||2,951||5,089|
|Total long-term liabilities||21,409||26,862|
|COMMITMENTS AND CONTINGENCIES|
|Additional paid-in capital||88,998||87,319|
|Accumulated other comprehensive loss, net of tax||(8,840||)||(8,611||)|
|Total shareholders’ equity||240,277||234,242|
|TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY||$||297,095||$||294,209|
|EXACTECH, INC. AND SUBSIDIARIES|
|CONSOLIDATED STATEMENTS OF INCOME|
|(in thousands, except per share amounts)|
Three Month Periods
Ended March 31,
|COST OF GOODS SOLD||20,641||20,368|
|Sales and marketing||25,053||23,319|
|General and administrative||6,536||5,914|
|Research and development||6,224||5,070|
|Depreciation and amortization||4,659||4,324|
|Total operating expenses||42,472||38,627|
|INCOME (LOSS) FROM OPERATIONS||6,369||6,303|
|OTHER INCOME (EXPENSE):|
|Other income (loss)||143||40|
|Foreign currency exchange gain||562||494|
|Total other income (expense)||482||276|
|INCOME BEFORE INCOME TAX AND EQUITY IN LOSS OF INVESTEE||6,851||6,579|
|PROVISION FOR INCOME TAXES||2,224||2,177|
|INCOME BEFORE EQUITY IN LOSS OF INVESTEE||4,627||4,402|
|EQUITY IN LOSS OF INVESTEE, NET OF TAX||(43||)||—|
|BASIC EARNINGS PER SHARE||$||0.32||$||0.31|
|DILUTED EARNINGS PER SHARE||$||0.32||$||0.31|
|SHARES - BASIC||14,272||14,057|
|SHARES - DILUTED||14,454||14,173|
Non-GAAP Disclosure and Reconciliation
We present certain non-GAAP results as a supplement to our financial results based on GAAP, as we believe it is useful to exclude certain items in order to focus on what we regard to be a more reliable indicator of the underlying operating performance of our business. Because we operate internationally, we present the percentage change in sales by reporting segment on a constant currency basis, which is a non-GAAP financial measure. We calculate this change on a constant currency basis by translating current period sales at the comparable average historical exchange rates for the same period in the prior year. We believe that presenting the percentage change in sales on a constant currency basis assists in the understanding of actual sales fluctuations by excluding the impact of foreign currency fluctuations.
Additionally, we report on a non-GAAP basis adjusted sales, gross margin, operating expenses, income, and diluted earnings per share excluding charges related to the spine assets we sold January 2017. We believe the exclusion of spine sales and costs provides the reader with more comparable financials to better analyze the reported periods. The following items have been adjusted:
- Sales, cost of goods sold, and operating expenses from our spine products
- Transition charges related to the sale of our spine assets
- Personnel and severance costs related to the transition
Three Months March 31, 2017
|Three Months March 31, 2016||
|US Spine||Adjusted||Reported||US Spine||Adjusted||
|Income before income tax and equity in loss of investee||6,851||(515||)||7,366||6,579||(252||)||6,831||4.1||6.3|
|Equity in loss of investee||(43||)||—||(43||
|Net income (loss)||$||4,584||$||(378||)||$||4,962||$||4,402||$||(158||)||$||4,560||4.1||8.8|
We also provide adjusted forward looking guidance on diluted earnings per share for the full year for 2017. We believe this adjusted guidance will assist in comparative measures. The following reconciles the guidance ranges to expected guidance on a GAAP basis:
|Twelve Months Ended|
|December 31, 2017|
|Expected diluted EPS range on GAAP basis||$1.24 - $1.30|
|Adjustment: Spine asset divestiture||0.02|
|Adjusted total diluted EPS range||$1.26-$1.32|